Acute Microbial Switch
Acute Microbial Switch Study
Maastricht University Medical Center
28 participants
Jan 1, 2024
INTERVENTIONAL
Conditions
Summary
In this project the investigators will test if it is possible to measure changes in intestinal gas production after supplementation of a complex fiber mixture over a 36 hour period in both lean normoglycemic individuals and individuals with insulin resistance and/or prediabetes with overweight when compared with a placebo Changes in intestinal gas production will also be related to energy expenditure, substrate metabolism, microbial composition and related metabolites in feces, blood and urine.
Eligibility
Inclusion Criteria10
- Lean normoglycemic individuals:
- Lean (BMI ≥ 18.5 kg/m2 and ≤ 24.9 kg/m2 );
- Normal fasting glucose (plasma glucose \< 5.6 mmol/L) and a HOMA-IR\< 2.2
- Individuals with overweight/obesity and prediabetes/insulin resistance:
- Overweight/obesity (BMI ≥ 28 kg/m2 and ≤ 40 kg/m2 );
- insulin resistance (HOMA-IR\>2.2) and/or impaired fasting glucose (IFG: plasma glucose ≥ 5.6 mmol/l)
- For both subject groups:
- Aged 30 - 75 years;
- Normal blood pressure (systolic blood pressure 100-150mmHg, diastolic blood pressure 60-100 mmHg);
- Weight stable for at least 3 months (± 2 kg)
Exclusion Criteria17
- T2DM (defined as fasting plasma glucose ≥ 7.0 mmol/L)
- Gastroenterological diseases
- Abdominal surgery affecting the GI tract;
- Cardiovascular diseases, cancer, liver or kidney malfunction, disease with a life expectancy shorter than five years;
- Abuse of products;
- Alcohol (\> 15 standard units per week)
- Drugs
- Excessive nicotine use defined as \>20 cigarettes per day;
- Plans to lose weight or following of a hypocaloric diet
- Regular supplementation of pre- or probiotic products, use of pre- or probiotics three months prior to the start of the study;
- Intensive exercise training more than three hours a week;
- Use of most medications that influence glucose or fat metabolism, like some lipid lowering-drugs (e.g., PPAR γ or PPARα (fibrates) agonists), glucose-lowering agents (including all sulfonylureas, biguanides, α-glucosidase inhibitors, thiazolidinediones, repaglinide, nateglinide and insulin), inflammation (e.g., anti-inflammatory\* or immunosuppressive drugs) and anti-oxidants;
- Regular use of laxatives;
- Use of antibiotics in the last three months (antibiotics use can alter substantially the gut microbiota composition).
- Veganism
- Lactose intolerance
- For women: pregnancy or lactation
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Participants will undergo a two day supplementation of a complex fiber supplement vs. placebo with a two-week washout period between the two interventions in a randomized order
Participants will undergo a two day supplementation of a complex fiber supplement vs. placebo with a two-week washout period between the two interventions in a randomized order
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05764200